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Abstract
The aim of this review article is to review the pharmacology, pharmacokinetics, efficacy and safety 
of everolimus. Primary literature was obtained via MEDLINE. Studies and abstracts evaluating eve-
rolimus in solid organ transplantation were considered for evaluation. English-language studies and 
abstracts only were selected for inclusion. Everolimus, a proliferation signal inhibitor that prevents 
growth factor-induced cell proliferation, is effective in reducing the incidence of acute rejection in 
solid organ transplantation. This agent is also useful in reducing cyclosporine-related nephroto-
xicity. Everolimus directly inhibits vascular remodelling and intimal thickening, which are often 
associated with chronic rejection. Clinical trials have shown that everolimus is generally safe. The 
most commonly reported adverse events were haematologic effects and hyperlipidaemia. Everoli-
mus is the second proliferation signal inhibitor to be proven effective in preventing acute rejection 
in solid organ transplant recipients. However, its exact role in the transplant immunosuppressive 
armamentarium is still unknown.
Keywords
Everolimus; mToR inhibitor; Immunosuppressant; Renal transplant; Heart transplant; Solid organ 
transplant
Reviews in Health Care 2011; 2(4): 229-241
Corresponding author
Steven Gabardi, PharmD, BCPS
Brigham and Women’s Hospital,
75 Francis Street, Boston, MA 02115
Phone 617-732-7658 Fax 617-732-7507 
sgabardi@partners.org
Everolimus: a review of its 
pharmacologic properties and use 
in solid organ transplantation
Drugs
Disclosure
The authors have no conflicts of interest to disclose
Narrative  
review
230 Reviews in Health Care 2011; 2(4) © SEEd All rights reserved
Everolimus: a review of its pharmacologic properties and use in solid organ transplantation P. Huiras, S. Gabardi
Background
Advances in the field of immunology have led to the discovery of new intracellular targets for immu-
nosuppression. The mammalian target of rapamycin (mToR), or FK binding protein-12 (FKBP12)-
rapamycin-associated-protein pathway, represents one of these. This large protein kinase is an intra-
cellular convergence point for several biologic processes that are essential for cellular metabolism and 
proliferation [1]. Everolimus, like sirolimus, reversibly binds and activates cytoplasmic FKBP12. Once 
activated, growth factor-stimulated phosphorylation of p70 S6 kinase, a key enzyme in protein synthe-
sis, is inhibited and the cell cycle is arrested at the late G1 stage [1]. Therefore stimulatory hormonal 
and cytokine (interleukin-2 [IL-2], interleukin-15 [IL-15]) mediated proliferation is inhibited, provi-
ding the basis for everolimus activity in preventing T-cell mediated allograft rejection [1-5]. 
Everolimus has proven to be a useful agent in oncology and cardiology, but this review will focus on its 
application in transplant. The pharmacodynamic, pharmacokinetic, dosing, drug-drug interaction and 
adverse event profiles of everolimus will be reviewed first, followed by a brief summary of the literature 
supporting its use in solid organ transplant (SOT). 
Data source
A non-date restricted MEDLINE search was conducted for English-language articles using the terms 
everolimus, RAD, RAD001, SDZ RAD, Afinitor, Certican, Xience and Zortress. Data were available 
from July 1997 to July 2011. Selection focused on human pharmacology, pharmacokinetics and clinical 
data for transplantation only. Only data from fully published studies were included. 
Chemistry and pharmacodynamics
Everolimus is a macrolide derivative in which a 2-hydroxyethyl group has been introduced in position 
40 (40-O-(hydroxyethyl)-rapamycin) (Figure 1) [6]. This alkalation at the C40 position is what chemi-
cally distinguishes everolimus from sirolimus. Pharmacodynamically, it weakens the affinity of evero-
limus for the FKBP12 protein complex [7]. Clinically, this difference is of little consequence [7]. 
Pharmacokinetics
Absorption/distribution
Similar to its predecessor, everolimus is a substrate of P-glycoprotein (P-gp), a drug transport protein, 
which significantly impacts its bioavailability. Of the two agents, everolimus has a lower bioavailability 
(14% versus 20%) [8,9]. Peak drug concentration (Cmax) occurs within one to two hours, following an 
oral dose [8,10]. Everolimus has a large volume of distribution at 342 ± 107 l (range 128-589 l) [8]. It 
is highly bound to circulating red blood cells and plasma proteins [8,10]. Linear pharmacokinetics are 
observed with this agent and blood concentrations vary from 0.25 to 15 mg/dose [11-13]. The oral 
absorption of this medication is significantly delayed in the presence of concomitant fat ingestions 
resulting in a diminished Cmax and the overall exposure (AUC) of everolimus [14]. Patients should be 
advised to take this medication consistently with or without food.
Metabolism/excretion 
Everolimus is metabolized via CYP3A4 isoenzymes to inactive metabolites [8,15]. The half-life ranges 
18-35 hours with only a small fraction, less than 10%, of the drug being excreted unchanged in the 
urine [15]. Since it is primarily metabolized via the liver, hepatic impairment (Child-Pugh class B) may 
increase the t1/2 and dose adjustment may be necessary.
Dosing and therapeutic drug monitoring
For renal and cardiac transplant populations, patients are initiated on an oral dosing regimen of 0.75 
mg twice daily or 1.5 mg/day [5]. Doses are adjusted based on whole blood drug concentration moni-
toring [16,17]. The therapeutic efficacy and toxicity of everolimus are concentration dependent with 
a moderate amount of inter-patient variability [16-18]. Therapeutic drug monitoring (TDM) is very 
useful and is recommended in SOT recipients. Generally, concentrations of > 3 ng/ml are desirable 
when given with a CNI (Calcineurin Inhibitor) and trough levels > 8 ng/ml have been associated with 
increased toxicity [16,17]. Higher target levels (6-10 ng/ml) may be necessary to maintain efficacy with 
CNI withdrawal regimens. 
Drug-drug interactions
Everolimus is a substrate of the CYP3A4 isoenzyme and, therefore, powerful inhibitors, inducers, and 
other CYP3A4 substrates may affect everolimus concentrations. Conversely, everolimus may affect 
concentrations of other CYP3A4 substrates. CNIs, which are often used concomitantly in SOT, are 3A4 
substrates and thus these drug-drug interactions are well described [19]. 
Azole antifungals and macrolide antibiotics, known CYP3A4 inhibitors, significantly increase con-
centrations of everolimus to varying degrees. Ketaconazole given concomitantly can nearly quadruple 
everolimus Cmax when given to health volunteers (15 ± 4 ng/ml to 59 ± 13 ng/ml) [20]. Itraconazaole 
has been shown to reduce everolimus clearance by as much as 74% [19]. While macrolides, such as 
erythromycin and azithromycin, can decrease everolimus clearance up to 22% [19]. 
Figure 1. Chemical structures of everolimus and sirolimus
A = everolimus; B = sirolimus
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cally distinguishes everolimus from sirolimus. Pharmacodynamically, it weakens the affinity of evero-
limus for the FKBP12 protein complex [7]. Clinically, this difference is of little consequence [7]. 
Pharmacokinetics
Absorption/distribution
Similar to its predecessor, everolimus is a substrate of P-glycoprotein (P-gp), a drug transport protein, 
which significantly impacts its bioavailability. Of the two agents, everolimus has a lower bioavailability 
(14% versus 20%) [8,9]. Peak drug concentration (Cmax) occurs within one to two hours, following an 
oral dose [8,10]. Everolimus has a large volume of distribution at 342 ± 107 l (range 128-589 l) [8]. It 
is highly bound to circulating red blood cells and plasma proteins [8,10]. Linear pharmacokinetics are 
observed with this agent and blood concentrations vary from 0.25 to 15 mg/dose [11-13]. The oral 
absorption of this medication is significantly delayed in the presence of concomitant fat ingestions 
resulting in a diminished Cmax and the overall exposure (AUC) of everolimus [14]. Patients should be 
advised to take this medication consistently with or without food.
Metabolism/excretion 
Everolimus is metabolized via CYP3A4 isoenzymes to inactive metabolites [8,15]. The half-life ranges 
18-35 hours with only a small fraction, less than 10%, of the drug being excreted unchanged in the 
urine [15]. Since it is primarily metabolized via the liver, hepatic impairment (Child-Pugh class B) may 
increase the t1/2 and dose adjustment may be necessary.
Dosing and therapeutic drug monitoring
For renal and cardiac transplant populations, patients are initiated on an oral dosing regimen of 0.75 
mg twice daily or 1.5 mg/day [5]. Doses are adjusted based on whole blood drug concentration moni-
toring [16,17]. The therapeutic efficacy and toxicity of everolimus are concentration dependent with 
a moderate amount of inter-patient variability [16-18]. Therapeutic drug monitoring (TDM) is very 
useful and is recommended in SOT recipients. Generally, concentrations of > 3 ng/ml are desirable 
when given with a CNI (Calcineurin Inhibitor) and trough levels > 8 ng/ml have been associated with 
increased toxicity [16,17]. Higher target levels (6-10 ng/ml) may be necessary to maintain efficacy with 
CNI withdrawal regimens. 
Drug-drug interactions
Everolimus is a substrate of the CYP3A4 isoenzyme and, therefore, powerful inhibitors, inducers, and 
other CYP3A4 substrates may affect everolimus concentrations. Conversely, everolimus may affect 
concentrations of other CYP3A4 substrates. CNIs, which are often used concomitantly in SOT, are 3A4 
substrates and thus these drug-drug interactions are well described [19]. 
Azole antifungals and macrolide antibiotics, known CYP3A4 inhibitors, significantly increase con-
centrations of everolimus to varying degrees. Ketaconazole given concomitantly can nearly quadruple 
everolimus Cmax when given to health volunteers (15 ± 4 ng/ml to 59 ± 13 ng/ml) [20]. Itraconazaole 
has been shown to reduce everolimus clearance by as much as 74% [19]. While macrolides, such as 
erythromycin and azithromycin, can decrease everolimus clearance up to 22% [19]. 
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Conversely, rifampin, a known CYP3A4 inducer, has been shown to significantly increase the clearance 
of everolimus. In a pharmacokinetic study by Kovarik et al., the half-life of everolimus was shortened, 
on average, from 32 to 24 hours (p = 0.0001) and the Cmax of everolimus decreased by 58% (p = 0.0001) 
[21]. Concomitant use of these two agents warrants close monitoring of everolimus levels. 
Atorvastatin and pravastatin have been studied for their potential to influence the pharmacokinetics 
of everolimus [22]. These agents, which are often given concomitantly with everolimus to treat mToR-
induced hyperlipidaemia, were found to have no clinically significant effect on everolimus concentra-
tions [22]. 
Cyclosporine (CsA) is both a substrate and a mild inhibitor of CYP3A4. As such, it has the potential to 
increase everolimus exposure when given in combination. This effect was found to be dependent up the 
formulation of cyclosporine used in combination with everolimus [23]. Kovarik et al. found that only 
co-administered CsA-modified was found to increase Cmax concentrations of everolimus statistically 
(82%, p = 0.0001) while conventional CsA had little effect on this kinetic parameter (6%, p = ns). In 
contrast, everolimus has been found to have little effect on CsA pharmacokinetics [23]. 
Tacrolimus, also a substrate of CYP3A4, is affected by concomitant everolimus administration. A study 
conducted by Pascual et al. compared tacrolimus pharmacokinetics among patients randomized to 
receive everolimus at dose of either 1.5 or 3 mg/day along with corticosteroids and tacrolimus [24]. 
Even though patients in the 3 mg/day everolimus group received larger daily tacrolimus doses, mean 
tacrolimus Cmin was higher than the 1.5 mg/day everolimus group (11.1 vs. 9.4, p = 0.03). This drug-
drug interaction did not affect clinical outcomes in this study, but practitioners should be mindful that 
everolimus will affect tacrolimus levels. 
Adverse effects
The therapeutic efficacy of everolimus hinges on its ability to affect multiple cytokine and hormone 
driven pathways. Unfortunately, this nonspecific interruption of cellular signalling also accounts for 
many of the side effects seen with mToR inhibitors. 
Delayed wound healing and delayed graft function (DGF) are two adverse effects that have been associa-
ted with mToR inhibitor use. Following transplant multiple growth factors (vascular endothelial growth 
factors, platelet-derived growth factor, epidermal growth factor) may quicken healing. These growth 
factors require functional mToR enzymes for optimal signal transduction and sirolimus use, in particu-
lar, has been associated with anastomotic dehiscence in lung transplant when used immediately post-
transplant [25,26]. The need for caution with everolimus especially in other types of transplantation, 
is less clear. In a prospective, multicenter, open-label study by Albano et al., renal transplant recipients 
(RTR) were randomized to receive everolimus immediately or delayed until five weeks post-transplant 
[27]. All patients were given anti-IL-2 antibodies for induction and maintained on CsA, corticosteroids. 
In addition to these agents, the delayed everolimus group received mycophenolate mofetil (MMF) until 
the conversion to everolimus. No difference was seen in delayed wound healing events in the immediate 
versus the delayed everolimus group (40% vs. 41.9%, p = ns). Similarly the rates of DGF were nearly 
identical in the immediate and delayed groups 24.6% and 24.3% (p = ns). Studies such as this call into 
question whether everolimus clinically effects wound healing and delay graft function [27]. 
Cytomegalovirus (CMV) induced disease is a complication of overall immunosuppression. However, 
the rates of CMV seroconversion, viraemia and disease may be lower in patients given everolimus 
when compared to other immunosuppressive regimens [6,28,29]. 
Lipid disturbances, especially hyperlipidaemia, are well described following at least two to three weeks 
of everolimus therapy post transplant. Often medications to lower serum lipids are necessary especially 
in both cardiac and renal transplant patients. Other reported side effects include mouth ulcers, nausea/
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vomiting, headache, elevated transaminases, diabetes, skin lesions, pneumonitis, and a concentration 
dependent myelosuppression [30]. 
Lastly, while everolimus causes no direct nephrotoxic effects, its use was originally associated with in-
creases in serum creatinine compared to other anti-metabolites. In many of the initial studies decreases 
in renal dysfunction were thought to be due to the previously described drug-drug interaction between 
CsA modified and everolimus, resulting in higher CsA exposure. When CsA doses were adjusted ap-
propriately for this interaction based on CsA levels, renal function improved [28,31-34]. 
Clinical efficacy in solid organ transplant
Everolimus is approved for prevention of rejection in organ transplant recipients in over 70 countries 
worldwide and its use is supported by many published, peer-reviewed trials on everolimus, which will 
be presented below. The majority of published trials with everolimus in SOT were in kidney and heart 
transplant. This is not surprising since everolimus reduces smooth muscle cell proliferation and pre-
vent remodelling, both of which are advantageous in preventing chronic allograft nephropathy (CAN), 
seen in kidney transplant, and cardiac allograft vasculopathy (CAV), a known complication of heart 
transplant. Everolimus has also been studied in lung and liver transplant.
Kidney transplant
In the first phase II clinical trials examining the efficacy of this novel mToR inhibitor, everolimus was 
given in lieu of other antimetabolites such as mycophenolate or azathioprine (AZA). In one of the 
earliest phase II clinical trials published in 2002, everolimus was given in addition to tacrolimus at 
different doses [35]. In this prospective, six-month, multicenter, open-label study, all patients received 
induction with basiliximab and were maintained on corticosteroids and everolimus (dosed to trough 
levels: ≥ 3 ng/ml and < 12 ng/ml). Patients were divided into two groups: low dose tacrolimus (target 
trough levels: 4 to 7 ng/ml from day 1 to month 3, and 3 to 6 ng/ml from months 4 to 6) or standard 
dose tacrolimus (target trough levels: 8 to 11 ng/ml from months 1 to 3, and 7 to 10 ng/ml from months 
4 to 6). Biopsy proven acute rejection (BPAR) was evaluated at 6 months and found to be 14% in both 
groups. With efficacy being identical, this study began building a case for using everolimus as a means 
to decrease CNI exposure in RTR [35]. 
A very similar second phase II study (B156) was published in 2004 and evaluated everolimus and va-
rious levels of CsA exposure [33]. This again was a randomized, open label study but evaluated patients 
for three years. Similarly patients were induced with basiliximab and maintained on corticosteroids, 
however, the everolimus dose was fixed at 3 mg/day. Patients were randomized to receive either low 
dose CsA targeting a trough of 50 to 100 ng/ml or full-dose CsA targeting troughs of 125-250 ng/ml. 
Efficacy failure was measured via the composite endpoint of BPAR, graft loss, death, or loss to follow-
up at 6, 12 and 36 months. Statistically less patients experienced efficacy failure in the low dose CsA 
group at 6 months (3.4% vs. 15.1%, p = 0.046), 12 months (8.6% vs. 28.3, p = 0.012) and 36 months 
(17.2% vs. 35.8, p = 0.032) . Mean creatinine clearance rates were also higher in the low dose CsA group 
at 6 and 12 months. These results provided more strength to the argument that everolimus coupled to 
low dose CNI may lead better clinical efficacy with short-term preserved renal function [33]. 
Two phase III clinical trials (B201 and B251) published in 2005 evaluated everolimus at different doses 
(1.5 mg/day versus 3.0 mg/day) compared to immunosuppressive regimens containing mycopheno-
late. All patient received corticosteroids, and full dose CsA in these trials [31,32]. These studies were 
prospective, multicenter, with parallel group design and follow up to 3 years. Both were blinded up to 1 
year, at which time open label use of everolimus was allowed. A composite endpoint was again used and 
included biopsy-proven acute rejection (BPAR), graft loss, death, or loss to follow-up. No differences 
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in the composite endpoint were seen between the high and low dose everolimus groups in throughout 
both studies. The authors concluded that both doses were equally efficacious, however some safety con-
cerns were raised regarding the use of high dose CsA and the higher dose of everolimus [31,32]. 
In these studies, the protocol for blinding everolimus use was amended at one year specifically for 
concerns of nephrotoxicity with everolimus use. In those with nephrotoxicity, everolimus doses were 
titrated to levels < 3 ng/ml which halted serum creatinine increases. In both of these trials patients 
were receiving CsA-modified, which interacts with everolimus kinetically. It is important to note that 
when CsA levels were reduced renal function also improved, suggesting that TDM is necessary for both 
mToR and CNIs when used in combination.
In the light of the preliminary findings of increased renal dysfunction, two phase IIIb studies 
(A2306/2307) were conducted to determine the optimal CsA exposure to produce target efficacy whi-
le avoiding nephrotoxicity [36]. A similar design was used in these trials, however, patients in the 
A2306 trial received basiliximab for induction. Everolimus was given at a dose of either 1.5 or 3 mg/
day (adjusted to troughs of > 3 ng/ml) and patients were maintained on corticosteroids and low-dose 
CsA. In trial A2306, in patients that received basiliximab, the target CsA concentrations measured 2 
hours post-dose (CSA C2) were 500 to 700 ng/ml for weeks 0 to 8 and 350 to 450 ng/ml thereafter. In 
the other study A2306, CsA C2 targets were between 1000 to 1400 ng/ml for weeks 0 to 4, 700 to 900 
ng/ml for weeks 5 to 8, 550 to 650 ng/ml for weeks 9 to 12 and 350 to 450 ng/ml thereafter. The CsA 
C2 ranges in both of these trials represent lower than standard target ranges. The primary efficacy 
endpoint of renal function at 12 months was improved from the prior phase III trials (B251 and B201) 
with no increase in the secondary endpoint of efficacy failure compared to these earlier trials. When the 
individual components of the primary outcome were dissected, more BPAR was seen with everolimus 
1.5 mg/day in Study A2306 (25.0%) than in Study A2307 (13.7%). Because of this finding, it is though 
that anti-IL-2 receptor induction therapy may be beneficial in reducing the risk of early BPAR when 
used with a lower dose of everolimus. Combining data from all four of these phase III trials allowed 
authors to conclude that dosing everolimus to appropriate concentrations allows for the reduction of 
CsA concentrations without any significant detriment to efficacy or safety. This conclusion was most 
strongly supported in comparing data from Studies B201 (full-exposure CsA) and A2306 (reduced-
exposure CsA) which showed no difference in efficacy failure or renal function when CsA exposure 
was by 57% at 12 months. A recently published trial in 2010 by Tedesco Silva et al. verified that CsA 
exposure can be reduced by as much as 60% in patients treated with everolimus with no difference in 
outcomes compared to full dose CsA and mycophenolate [37]. 
Confirmation of the safety of everolimus when dose adjusted has led investigators to push the limits 
of traditional renal transplant pharmacotherapeutics and attempt to remove CNIs completely. Bud-
de et al. recently published one of the largest multicenter open-label controlled trials evaluating CNI 
withdrawal in RTR (The Zeus Trial) [38]. All patients were induced with basiliximab and maintained 
immediately post transplant on corticosteroids, mycophenolate sodium, and CsA based on trough con-
centration. At 4.5 months post transplant those randomized to be converted to everolimus based regi-
mens received 1.5 mg/day titrated to a target trough concentration in conjunction with de-escalation 
of CsA concentrations in a stepwise fashion. CsA levels were titrated to 50% of standard concentrations 
in step 1, 25% of goal in step 2 and 0% in step 3, which occurred over 4 weeks or less. Everolimus tar-
get levels in step 1 were 3 to 8 ng/ml and 6 to 10 ng/ml thereafter. At 12 months patients converted 
to everolimus had significantly higher glomerular filtration rates (GFR) versus those continued on 
CsA (71.8% vs. 61.9%, p < 0.001). Rates of BPAR were similar to 15% for both groups at 12 months. 
Consistent with other trials, higher mean lipid concentrations, urinary protein excretion and lower 
haemoglobin values were seen in the everolimus group [38]. Overall the results of trials such as these 
in RTR has bolstered the interest of using everolimus in other types of organ transplant especially in 
cases where CNIs are not well tolerated. 
The main trials about the use of everolimus in renal transplantation are summarized in Table I.
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in the composite endpoint were seen between the high and low dose everolimus groups in throughout 
both studies. The authors concluded that both doses were equally efficacious, however some safety con-
cerns were raised regarding the use of high dose CsA and the higher dose of everolimus [31,32]. 
In these studies, the protocol for blinding everolimus use was amended at one year specifically for 
concerns of nephrotoxicity with everolimus use. In those with nephrotoxicity, everolimus doses were 
titrated to levels < 3 ng/ml which halted serum creatinine increases. In both of these trials patients 
were receiving CsA-modified, which interacts with everolimus kinetically. It is important to note that 
when CsA levels were reduced renal function also improved, suggesting that TDM is necessary for both 
mToR and CNIs when used in combination.
In the light of the preliminary findings of increased renal dysfunction, two phase IIIb studies 
(A2306/2307) were conducted to determine the optimal CsA exposure to produce target efficacy whi-
le avoiding nephrotoxicity [36]. A similar design was used in these trials, however, patients in the 
A2306 trial received basiliximab for induction. Everolimus was given at a dose of either 1.5 or 3 mg/
day (adjusted to troughs of > 3 ng/ml) and patients were maintained on corticosteroids and low-dose 
CsA. In trial A2306, in patients that received basiliximab, the target CsA concentrations measured 2 
hours post-dose (CSA C2) were 500 to 700 ng/ml for weeks 0 to 8 and 350 to 450 ng/ml thereafter. In 
the other study A2306, CsA C2 targets were between 1000 to 1400 ng/ml for weeks 0 to 4, 700 to 900 
ng/ml for weeks 5 to 8, 550 to 650 ng/ml for weeks 9 to 12 and 350 to 450 ng/ml thereafter. The CsA 
C2 ranges in both of these trials represent lower than standard target ranges. The primary efficacy 
endpoint of renal function at 12 months was improved from the prior phase III trials (B251 and B201) 
with no increase in the secondary endpoint of efficacy failure compared to these earlier trials. When the 
individual components of the primary outcome were dissected, more BPAR was seen with everolimus 
1.5 mg/day in Study A2306 (25.0%) than in Study A2307 (13.7%). Because of this finding, it is though 
that anti-IL-2 receptor induction therapy may be beneficial in reducing the risk of early BPAR when 
used with a lower dose of everolimus. Combining data from all four of these phase III trials allowed 
authors to conclude that dosing everolimus to appropriate concentrations allows for the reduction of 
CsA concentrations without any significant detriment to efficacy or safety. This conclusion was most 
strongly supported in comparing data from Studies B201 (full-exposure CsA) and A2306 (reduced-
exposure CsA) which showed no difference in efficacy failure or renal function when CsA exposure 
was by 57% at 12 months. A recently published trial in 2010 by Tedesco Silva et al. verified that CsA 
exposure can be reduced by as much as 60% in patients treated with everolimus with no difference in 
outcomes compared to full dose CsA and mycophenolate [37]. 
Confirmation of the safety of everolimus when dose adjusted has led investigators to push the limits 
of traditional renal transplant pharmacotherapeutics and attempt to remove CNIs completely. Bud-
de et al. recently published one of the largest multicenter open-label controlled trials evaluating CNI 
withdrawal in RTR (The Zeus Trial) [38]. All patients were induced with basiliximab and maintained 
immediately post transplant on corticosteroids, mycophenolate sodium, and CsA based on trough con-
centration. At 4.5 months post transplant those randomized to be converted to everolimus based regi-
mens received 1.5 mg/day titrated to a target trough concentration in conjunction with de-escalation 
of CsA concentrations in a stepwise fashion. CsA levels were titrated to 50% of standard concentrations 
in step 1, 25% of goal in step 2 and 0% in step 3, which occurred over 4 weeks or less. Everolimus tar-
get levels in step 1 were 3 to 8 ng/ml and 6 to 10 ng/ml thereafter. At 12 months patients converted 
to everolimus had significantly higher glomerular filtration rates (GFR) versus those continued on 
CsA (71.8% vs. 61.9%, p < 0.001). Rates of BPAR were similar to 15% for both groups at 12 months. 
Consistent with other trials, higher mean lipid concentrations, urinary protein excretion and lower 
haemoglobin values were seen in the everolimus group [38]. Overall the results of trials such as these 
in RTR has bolstered the interest of using everolimus in other types of organ transplant especially in 
cases where CNIs are not well tolerated. 
The main trials about the use of everolimus in renal transplantation are summarized in Table I.
1st Author 
[Study]
Year No. pts. Intervention Outcome Conclusions
Chan 
(US09) [35]
2002 92 Low dose tacrolimus versus 
standard dose tacrolimus 
in patients induced with 
basiliximab receiving 
everolimus (targeted to troughs 
> 3 ng/ml) and corticosteroids 
No difference in BPAR in either 
low or high dose group at 6 
months
Everolimus and low dose 
tacrolimus is efficacious in 
RTR
Nashan 
(B126) [33]
2004 111 Low dose CsA versus standard 
dose CsA in patients induced 
with basiliximab and receiving 
everolimus 3 mg/day and 
corticosteroids 
The composite endpoint of BPAR, 
graft loss, death, or loss to follow-
up was statistically lower at 6, 12, 
and 36 months in the low dose 
CsA group. Creatinine clearance 
was also lower in the low dose 
CsA group
Everolimus and low dose 
CsA maybe more effective 
and less toxic than 
everolimus and standard 
dose CsA
Vitko (B201) 
[31]
2005 588 Everolimus 1.5 mg or 3 mg/
day compared to MMF in 
patients receiving standard 
dose CsA and corticosteroids
No difference in BPAR, graft 
loss, death or loss to follow-up 
in either of the groups. Serum 
creatine was lower in the MMF 
group
Both doses of everolimus 
were efficacious, but renal 
toxicity in conjunction with 
full dose CsA remains a 
concern
Vitko 
(A2306) [36]
2004 237 Everolimus 1.5 versus 3 
mg/day (both adjusted to 
troughs > 3 ng/ml) in patients 
receiving CsA (adjusted to 
lower than standard trough 
values) and corticosteroids
No difference in renal function 
was seen between the two doses 
of everolimus. No difference 
in BPAR, graft loss or death 
between the two groups
Concentration adjusted 
everolimus coupled to 
concentration controlled 
CsA results in acceptable 
efficacy without excessive 
nephrotoxity
Vitko 
(A2307) 
[36]
2004 256 Everolimus 1.5 versus 3 mg/
day (adjusted to troughs > 
3 ng/ml) in patients induced 
with basiliximab and receiving 
CsA (adjusted to lower than 
standard trough values) and 
corticosteroids
No difference in renal function 
was seen between the two doses 
of everolimus. No difference in 
BPAR, graft loss or death between 
the two groups. However less 
BPAR was seen in the everolimus 
1.5 mg/day group in this study 
compared to the prior study in 
the 1.5 mg/day group
Concentration adjusted 
everolimus coupled to 
concentration controlled 
CsA results in acceptable 
efficacy without excessive 
nephrotoxity. When using 
low dose everolimus 
basiliximab induction may 
help prevent BPAR
Lorber 
(B251) [32]
2005 583 Everolimus 1.5 or  
3 mg/day compared to MMF 
2 g/day in patients receiving 
standard dose CsA and 
corticosteroids 
No difference in the composite 
endpoint of biopsy-proven acute 
rejection, graft loss, death, or loss 
to follow-up between the two 
groups. Serum creatinine was 
lower in the MMF group
Both doses of everolimus 
(1.5 or 3 mg/day) were 
efficacious, but higher 
doses may have resulted 
in a higher incidence in 
nephrotoxicity compared 
to MMF. Combined use 
with CsA requires dose 
adjustments of CsA and 
everolimus to limit toxicity
Budde 
(Zues) [38]
2010 503 Conversion of CsA based 
regimen to everolimus based 
at 4.5 months post transplant
Everolimus conversion was 
associated with a significant 
improvement in GFR at 6 
months, but not at 12 months 
post transplant. No difference 
in BPAR was seen at 12 month 
between the two groups
Everolimus conversion 
therapy in RTR is safe and 
efficacious
Table I. Review of selected literature in renal transplantation
BPAR = biopsy proven acute rejection; CsA = cyclosporine; GFR = glomerular filtration rate; MMF = 
mycophenolate mofetil; RTR = renal transplant recipients
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Heart transplant
Similar to the progression seen in kidney transplant, everolimus was first studied in place of anti-
metabolites in heart transplantation [28,39,40]. While CNI reduction and removal with everolimus use 
in this population have been promising, it has yet to be assessed in a randomized controlled fashion 
[41,42]. 
A large randomized controlled trial of over 600 patients was conducted by Eisen et al. in heart tran-
splant recipients comparing everolimus to AZA [28]. All patients were maintained on CsA and cor-
ticosteroids. Patients received everolimus at 1.5 mg/day (n = 209) or 3 mg/day (n = 211), or AZA at 
a dose of 1-3 mg/kg/day of (n = 214). The primary composite endpoint consisted of death, graft loss, 
retransplantation, lost to follow-up and biopsy proven acute rejection of grade 3A or rejection with 
haemodynamic compromise seen within the first six months following transplantation. They were also 
assessed in a 24-month follow-up to this study [39]. More patients attained the primary endpoint at 6 
months in the AZA group (46.7%) compared to those receiving everolimus at either dose (1.5 mg/day 
= 36.4%, p = 0.03; 3 mg/day = 27%, p < 0.001) [28]. The incidence of the composite endpoint remained 
lower at 24 months in patients treated with everolimus (1.5 mg/day = 45.9%, p = 0.016; 3 mg/day = 
36%, p < 0.001) versus AZA (57.5%) [39]. CAV was significantly lower with everolimus (1.5 mg/day = 
35.7%, p = 0.045; 3 mg/day = 30.4%, p = 0.01) than with AZA (52.8%) at 6 months [28]. However, at 
24 months only the low dose everolimus group retained a statistical difference in rates of vasculopathy 
at 33.3% compared 58.3% with AZA (p = 0.017) [39]. At 6 months everolimus use was associated with 
a decrease in CMV rates in both groups (1.5 mg/day = 7.7%, p < 0.001; 3 mg/day = 7.6%, p < 0.001) 
compared to AZA (21.5%). At 6 and at 24 months serum creatinine levels were significantly higher in 
the two everolimus compared to the AZA group, but decreased when CsA exposure was reduced. As in 
the early trials with everolimus and CsA combinations, renal dysfunction was attributed to higher CsA 
exposure. Not only did these trials establish the safety and efficacy of everolimus for heart transplant, 
but this agent proved to be effective in reducing CAV, a major contributor to late allograft failure and 
mortality [39]. 
Everolimus has also been studied prospectively in a randomized fashion compared to mycophenolate 
mofetil in heart transplant recipients [40]. While some patients received induction therapy and others 
did not, all patients were maintained on corticosteroids. Patients were randomized to be maintained 
on either everolimus titrated to a trough of 3 to 8 ng/ml with reduced-dose CsA versus MMF 3 g/
day with full dose CsA. The primary endpoint was the effect of the two regimens on post-transplant 
renal function. All efficacy endpoints for everolimus were deemed non-inferior to MMF at 12 mon-
ths posttransplant. Although calculated creatinine clearance was 6.9 ml/min lower with everolimus 
compared to MMF at 6 months, this difference decreased to only 3.1 ml/min by 12 months. Lower 
rates of CMV infections were seen in the everolimus group at 4.4% versus the MMF group 16.9% (p = 
0.01). Concentration-controlled everolimus with reduced-dose CsA was just as efficacious and safe as 
MMF administered concomitantly with standard-dose CsA following cardiac transplantation in this 
12-month controlled trial [40].
Liver transplant
To evaluate the safety and tolerability Levy et al. compared everolimus at various doses in addition 
to CsA and corticosteroids in liver transplant recipients (n = 119) [43]. Patients were randomized to 
receive everolimus at 2 mg/day, 4mg/day or placebo in a double-blind fashion. Those patients receiving 
4 mg/day had numerically higher adverse events, but statistically the percent of adverse events were 
similar between all groups. Numerically less episodes of acute rejections were seen with everolimus 
treatment, but again the differences did not attain statistical significance. This study confirmed that 
everolimus is safe to use in conjunction with CsA and corticosteroids in liver transplant [43]. 
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Two CNI conversion studies have been conducted with everolimus in liver transplant recipients [44]. 
The smaller of the two (n = 10) conducted in patients with new or recurrent hepatocarcinomas post-
transplant showed no case of acute rejection and an acceptable level of adverse events [44]. The larger 
trial (n = 40) included patients that had CNI intolerance such as nephrotoxicity, microangiopathy or 
peripheral neuropathy [34]. A successful outcome was documented as a conversion to monotherapy 
with 1.5 mg/day within 4 weeks. Treatment failure was defined as the presence of continued use of a 
CNI, patient death, and graft loss. At 12 months 75% of patients were successfully converted over and 
the patient and graft survival was 100%. Patients that were successfully converted to everolimus had 
improvement in calculated creatinine clearance compared to baseline (p < 0.0001) [34]. While these 
two trials highlight the usefulness of everolimus in rescue situations, they also provide insight into the 
potential of using everolimus based therapy in liver transplant. 
Lung transplant
The efficacy of everolimus has been evaluated in one large (n = 213) randomized double blinded study 
by Snell et al. Only patients with stable allograft function were included [45]. All patients received 
CsA and corticosteroids while 101 patients were randomized to initiate everolimus 3 mg/day and 112 
patients remained on AZA. A composite endpoint of decline in forced expiratory volume in 1 second 
(FEV1) of > 15% from baseline, graft loss, death or lost to follow-up was used as evidence of treatment 
failure. At twelve months treatment failure was seen in 21.8% of the everolimus patients versus 33.9% 
in the AZA patients (p = 0.046). This difference was not significant at 24 months. Although not part of 
the composite endpoint, the percentage of patients experiencing acute rejection was statistically lower 
in the everolimus group throughout the trial. Everolimus use was associated with significantly more 
infections and adverse events such as hyperlipidemia and myelosuppression [45]. 
Evidence in paediatrics
A small analysis (n = 19) of everolimus 1.6 mg/m2/day was conducted de novo in paediatric RTR. Pa-
tients received everolimus, corticosteroids and CsA-modified for 6 months [46]. No deaths, graft losses 
or losses to follow-up were documented; however 16% BPAR was seen within this time period. Eighte-
en of the 19 patients experienced an adverse event including hyperlipidemia, bacterial infections, and 
lymphocele formation. Kinetic analysis revealed that weight, body-surface area and weight were all 
positively correlated to everolimus clearance. This study provided some insight into the efficacy and 
dosing considerations in pediatric patients [46]. 
In hopes of stabilizing biopsy proven transplant nephropathy everolimus was evaluated in 13 pediatric 
patients [47]. After CsA reductions by 50% and discontinuation of all other immunosuppressants, eve-
rolimus therapy was initiated and titrated to a target concentration of 3 to 6 ng/ml. In this small study, 
initiation of everolimus resulted in no cases BPAR, further decline in renal function or significant 
adverse events [47]. While these two analyses of pediatric patients are small unblinded and not rando-
mized, they represent the reported outcomes with everolimus use in pediatric SOT.
Conclusions
Everolimus has a reduced half-life, poorer bioavailability, and binds less tightly to the FKBP12 binding 
complex compared to sirolimus. The influence of these pharmacokinetic and dynamic differences on 
efficacy is difficult to elucidate. What is known is everolimus reaches steady state quicker, exhibits line-
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ar pharmacokinetics, and TDM can be utilized to ensure the efficacy of this agent. The most common 
adverse reactions with this agent remain hyperlipidemia and myelosuppression. 
The majority of literature published with everolimus for SOT is in kidney and heart transplantation. In 
these populations, everolimus decreased CAV and CAN, both of which are associated with poor graft 
function and increased mortality. Everolimus has been compared to both antimetabolite therapies 
(mycophenolate and AZA) and has proven to 
be equally efficacious. Some of the most encou-
raging data centers on using everolimus to de-
crease CNI exposure, sparing transplant pa-
tients from the deleterious effects of CNI-indu-
ced nephropathy. While some level 1 evidence 
has been recently published supporting CNI-
free immunosuppressive regimens in kidney 
transplantation, more literature is needed to 
further define the benefits of mToR based im-
munosuppression with everolimus. 
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